Market PositioningRecent setbacks for drugs targeting the muscarinic system as an alternative to the current selection of atypical antipsychotics have left Brilaroxazine as one of the few viable Phase 3 assets in the space.
Safety ProfileThe long-term safety profile remained positive as well, with a 35% discontinuation rate that compares favorably to the 60%-70% typically seen in similar-duration trials of other antipsychotics.
Therapeutic PotentialBrilaroxazine demonstrated sustained, dose-dependent efficacy across all key symptom domains (positive, negative, cognitive, agitation), underscoring its therapeutic potential in treating schizophrenia.